AT-Patch (ATP-C130/ATP-C70) vs Autoplaque
AI Verdict
Choose AT-Patch (ATP-C130/ATP-C70) if…
Choose AT-Patch if you require extended, continuous cardiac monitoring for arrhythmia detection in an ambulatory setting. Its lightweight, shower-proof design and up to 14 days of monitoring without intervention make it ideal for capturing intermittent or elusive cardiac events while patients maintain their daily activities.
View AT-Patch (ATP-C130/ATP-C70) →Choose Autoplaque if…
Choose Autoplaque if you need AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This tool is best suited for clinicians focused on detailed risk stratification for heart attack and guiding treatment decisions based on precise measurements of atherosclerotic burden.
View Autoplaque →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AT-Patch (ATP-C130/ATP-C70) | Autoplaque |
|---|---|---|
| Deployment | Wearable device for patients; analysis software deployed on-premise at medical institutions. | Workstation-based post-processing application, runs on Windows or Mac OS. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AT-Patch (ATP-C130/ATP-C70)AT-Patch appears to have a higher degree of patient-centric usability due to its wearable, shower-proof design, and companion smartphone app for live ECG viewing and symptom recording. Autoplaque, while offering automated analysis, is a workstation-based post-processing application requiring trained medical professionals, which suggests a more specialized and less broadly accessible user experience.
Clinical Value
TieBoth tools offer significant clinical value within their respective domains. AT-Patch provides continuous, long-term ECG monitoring for arrhythmia detection, addressing the challenge of intermittent cardiac events. Autoplaque offers AI-powered quantitative analysis of coronary plaques from CT angiography, which is crucial for heart attack risk prediction and treatment guidance. Both are FDA-cleared and backed by clinical validation.
Pricing & Value
TieNeither company publicly discloses pricing information, making a direct comparison of pricing and value difficult. Both products are likely sold through direct sales to medical institutions, with costs varying based on institutional needs and agreements. Without transparent pricing, it's impossible to determine which offers better financial value.
Enterprise Readiness
AutoplaqueAutoplaque, as a workstation-based post-processing application that runs on Windows or Mac OS and exports DICOM image data, seems more inherently designed for integration into existing hospital radiology and cardiology workflows. AT-Patch's analysis software is deployed on-premise, but the wearable component and data transfer process might introduce different integration considerations for large-scale enterprise deployment.
Innovation
TieBoth tools demonstrate significant innovation in their respective fields. AT-Patch offers a compact, long-duration wearable ECG monitor with integrated AI for arrhythmia detection. Autoplaque leverages advanced AI for automated, quantitative analysis of complex coronary plaque characteristics from CT angiography, a critical step in cardiovascular risk assessment.
Support & Docs
TieSpecific details regarding the comprehensiveness of support and documentation for both AT-Patch and Autoplaque are not extensively available in the provided information or public web searches. Both are FDA-cleared medical devices, implying a certain standard of documentation and support, but a comparative assessment is not possible.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AT-Patch (ATP-C130/ATP-C70) | Autoplaque |
|---|---|---|
| Name | AT-Patch (ATP-C130/ATP-C70) | Autoplaque |
| Company | ATsens Co. | Cedars-Sinai Medical Center: AIM |
| Description | FDA-cleared wearable ECG monitor offering up to 14 days of continuous cardiac monitoring with high accuracy, a shower-proof design, and integrated AI-powered analysis software for enhanced arrhythmia detection. | FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. |
| Categories | Cardiology AI, Wearables & Remote Monitoring (RPM) | Cardiology AI, Radiology & Imaging AI |
| Specialties | Cardiology, Family Medicine, Internal Medicine | Cardiology, Radiology |
| Key Features | Up to 14 days of continuous ECG monitoring (ATP-C130), High-performance sensor chip for accurate ECG signal acquisition, Short-length electrode to minimize motion artifact noise, Shower-proof design (IP57 for ATP-C130, IP44 for ATP-C70), No charging or electrode replacement required during monitoring, Compact and lightweight (13g) for patient comfort, AT-Note smartphone app for live ECG viewing and symptom recording, AT-Report software with AI/machine learning algorithms for ECG analysis | AI-powered quantitative analysis of atherosclerotic plaque, Detection and characterization of coronary artery plaque, Measurement of luminal stenoses, Analysis of coronary anatomy and pathology from CT Angiographic images, Workstation-based post-processing application, Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician), Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views, Measurement of vessel diameter and area |
Videos
Demos, reviews, and walkthroughs featuring AT-Patch (ATP-C130/ATP-C70) and Autoplaque.